Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tafenoquine · Arakoda, Krintafel

Small molecule · developed by Glaxosmithkline

Approved FDA, Jul 2018
3 Registered trials

What is Tafenoquine?

Tafenoquine is an 8-aminoquinoline antimalarial drug.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Arakoda, Krintafel, SB-252263-AAB, ARAKODA, KODATEF
Drug type
Small molecule
Therapy area
Infectious disease
Developer
Glaxosmithkline
In trials of
SXTP
FDA status
Approved as Arakoda, Krintafel (July 20, 2018), NDA210795 · FDA label
UNII
262P8GS9L9

✅ FDA-approved uses

From the indications section of the FDA label (version of Jan 10, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06656351 Phase 2 Chronic Babesiosis Recruiting SXTP
NCT06207370 Phase 2 Babesiosis Recruiting SXTP
NCT04533347 Phase 2 COVID 19 Disease Completed SXTP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

BabesiosisChronic BabesiosisCOVID 19 Disease

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.